Patents-Review.com
🔗 Permalink
Assignee profile:

Seattle Genetics, Inc.

City:

Bothell, Washington

Country:

United States

Published Applications:

223

Last publication date:

2023-01-05

Patent Grants:

155

Last grant date:

2023-10-24

Quarterly Seattle Genetics, Inc. Patent Applications

Top Inventors for applications by Seattle Genetics, Inc.

These are the the leading inventors for applications assigned to Seattle Genetics, Inc.:

Recent patent applications by Seattle Genetics, Inc.

Seattle Genetics, Inc. based in Bothell, US has been assigned the rights to these inventions. The list includes both Pending Applications and Patent Grants:

#1 | 2023-01-05
US20230002440A1
Chemistry; metallurgy

ALTERNATIVE PROCESSES FOR THE PREPARATION OF TUBULYSINS AND INTERMEDIATES THEREOF

 #2 | 2022-09-22
US20220298243A1
Chemistry; metallurgy

ANTI-PD-1 ANTIBODY IN COMBINATION WITH AN ANTI-CD30 ANTIBODY IN CANCER TREATMENT

 #3 | 2021-07-22 ✅ Patent 11,795,229 granted on 2023-10-24
US20210221901A1
Chemistry; metallurgy

Methods of reducing side effects of anti-CD30 antibody drug conjugate therapy

 #4 | 2021-02-18
US20210047404A1
Chemistry; metallurgy

CD33 ANTIBODIES AND USE OF SAME TO TREAT CANCER

 #5 | 2021-01-21
US20210017213A1
Chemistry; metallurgy

Glycan Analysis and Profiling

 #6 | 2021-01-14
US20210011021A1
Physics

Glycan-Interacting Compounds and Methods of Use

 #7 | 2021-01-14 ✅ Patent 11,857,565 granted on 2024-01-02
US20210008099A1
Human necessities

Hydrophobic Auristatin F compounds and conjugates thereof

 #8 | 2021-01-07
US20210002380A1
Chemistry; metallurgy

Humanized Anti-CD70 Binding Agents and Uses Thereof

 #9 | 2020-10-01 ✅ Patent 10,940,178 granted on 2021-03-09
US20200306336A1
Human necessities

Weekly dosing regimens for anti-CD30 vc-PAB-MMAE antibody drug-conjugates

 #10 | 2020-09-24 ✅ Patent 11,389,543 granted on 2022-07-19
US20200297864A1
Human necessities

Process for the preparation of tubulysins and intermediates thereof

 #11 | 2020-09-17
US20200289661A1
Human necessities

CD48 ANTIBODIES AND CONJUGATES THEREOF

 #12 | 2020-09-03
US20200276306A1
Human necessities

Glycan-Interacting Compounds and Methods of Use

 #13 | 2020-08-06
US20200247902A1
Chemistry; metallurgy

COMPOSITIONS AND METHODS FOR TREATING CANCER

 #14 | 2020-07-23
US20200230254A1
Human necessities

COMBINATION THERAPY USING A CD19-ADC AND RCHP

 #15 | 2020-07-16 ✅ Patent 11,730,822 granted on 2023-08-22
US20200222553A1
Human necessities

Process for the preparation of glucuronide drug-linkers and intermediates thereof

 #16 | 2020-06-25 ✅ Patent 11,931,414 granted on 2024-03-19
US20200197524A1
Human necessities

Quaternized nicotinamide adenine dinucleotide salvage pathway inhibitor conjugates

 #17 | 2020-04-09 ✅ Patent 11,366,118 granted on 2022-06-21
US20200110091A1
Physics

Detection and treatment of CD30 cancers

 #18 | 2020-02-27
US20200063180A1
Chemistry; metallurgy

PREPARING ANTIBODIES FROM CHO CELL CULTURES FOR CONJUGATION

 #19 | 2020-02-27 ✅ Patent 11,401,339 granted on 2022-08-02
US20200062859A1
Chemistry; metallurgy

Anti-TIGIT antibodies

 #20 | 2020-02-27
US20200062857A1
Chemistry; metallurgy

VARIANT TARGET BINDING AGENTS AND USES THEREOF

 #21 | 2020-02-27 ✅ Patent 11,033,561 granted on 2021-06-15
US20200061091A1
Human necessities

Methods of inhibition of protein fucosylation in vivo using fucose analogs

 #22 | 2020-02-06
US20200040082A1
Chemistry; metallurgy

Anti-TIGIT Antibodies

 #23 | 2020-01-30
US20200031938A1
Chemistry; metallurgy

ANTIBODIES TO INTEGRIN AVB6 AND USE OF SAME TO TREAT CANCER

 #24 | 2020-01-30 ✅ Patent 10,722,549 granted on 2020-07-28
US20200030405A1
Human necessities

Weekly dosing regimens for anti-CD30 vc-PAB-MMAE antibody drug-conjugates

 #25 | 2020-01-02 ✅ Patent 11,078,291 granted on 2021-08-03
US20200002431A1
Chemistry; metallurgy

BCMA antibodies and use of same to treat cancer and immunological disorders

 #26 | 2020-01-02 ✅ Patent 11,253,609 granted on 2022-02-22
US20200000932A1
Human necessities

Glycan-interacting compounds and methods of use

 #27 | 2019-12-26 ✅ Patent 11,844,839 granted on 2023-12-19
US20190388546A1
Human necessities

Process for the preparation of pegylated drug-linkers and intermediates thereof

 #28 | 2019-12-19
US20190381172A1
Human necessities

STABLE FORMULATIONS FOR ANTI-CD19 ANTIBODIES AND ANTIBODY-DRUG CONJUGATES

 #29 | 2019-12-12
US20190375841A1
Chemistry; metallurgy

ANTI-NTB-A ANTIBODIES AND RELATED COMPOSITIONS AND METHODS

 #30 | 2019-11-21 ✅ Patent 11,230,610 granted on 2022-01-25
US20190352428A1
Chemistry; metallurgy

Bivalent antibodies masked by coiled coils

 #31 | 2019-11-14
US20190343828A1
Human necessities

CAMPTOTHECIN PEPTIDE CONJUGATES

 #32 | 2019-11-07 ✅ Patent 10,808,039 granted on 2020-10-20
US20190338045A1
Chemistry; metallurgy

Monomethylvaline compounds capable of conjugation to ligands

 #33 | 2019-11-07 ✅ Patent 10,561,739 granted on 2020-02-18
US20190336614A1
Human necessities

Targeted pyrrolobenzodiazapine conjugates

 #34 | 2019-10-17 ✅ Patent 11,638,762 granted on 2023-05-02
US20190314519A1
Human necessities

Targeted delivery of nicotinamide adenine dinucleotide salvage pathway inhibitors

 #35 | 2019-09-26 ✅ Patent 10,828,375 granted on 2020-11-10
US20190290777A1
Human necessities

Distribution of engineered-cysteine caps

 #36 | 2019-08-29 ✅ Patent 11,191,771 granted on 2021-12-07
US20190262354A1
Human necessities

Combinations of PBD-based antibody drug conjugates with FLT3 inhibitors

 #37 | 2019-07-25 ✅ Patent 10,478,469 granted on 2019-11-19
US20190224268A1
Human necessities

Weekly dosing regimens for anti-CD30 vc-PAB-MMAE antibody drug-conjugates

 #38 | 2019-07-18 ✅ Patent 11,299,543 granted on 2022-04-12
US20190218293A1
Chemistry; metallurgy

Use of an anti-PD-1 antibody in combination with an anti-CD30 antibody in cancer treatment

 #39 | 2019-06-27
US20190194338A1
Chemistry; metallurgy

BCMA ANTIBODIES AND USE OF SAME TO TREAT CANCER AND IMMUNOLOGICAL DISORDERS

 #40 | 2019-06-20 ✅ Patent 11,180,552 granted on 2021-11-23
US20190185561A1
Chemistry; metallurgy

CD47 antibodies and uses thereof for treating cancer

 #41 | 2019-06-06 ✅ Patent 11,944,689 granted on 2024-04-02
US20190167806A1
Human necessities

Drug conjugates with self-stabilizing linkers having improved physiochemical properties

 #42 | 2019-05-09 ✅ Patent 11,110,179 granted on 2021-09-07
US20190134215A1
Human necessities

Combination of CD33 antibody drug conjugates with chemotherapeutic agents

 #43 | 2019-04-25
US20190117787A1
Human necessities

COMBINATIONS OF CD33 ANTIBODY DRUG CONJUGATES WITH HYPOMETHYLATING AGENTS

 #44 | 2019-03-21 ✅ Patent 11,325,980 granted on 2022-05-10
US20190085091A1
Chemistry; metallurgy

Combination therapy using a LIV1-ADC and a chemotherapeutic

 #45 | 2019-03-14 ✅ Patent 11,027,021 granted on 2021-06-08
US20190076549A1
Human necessities

Combinations of PBD-based antibody drug conjugates with Bcl-2 inhibitors

 #46 | 2019-01-24
US20190023801A1
Chemistry; metallurgy

BCMA ANTIBODIES AND USE OF SAME TO TREAT CANCER AND IMMUNOLOGICAL DISORDERS

 #47 | 2019-01-17 ✅ Patent 11,229,708 granted on 2022-01-25
US20190015517A1
Human necessities

Conjugates of quaternized tubulysin compounds

 #48 | 2018-12-27 ✅ Patent 10,391,181 granted on 2019-08-27
US20180369408A1
Human necessities

Cyclodextrin and antibody-drug conjugate formulations

 #49 | 2018-12-13
US20180353524A1
Human necessities

CANCER TREATMENT USING 2-DEOXY-2-FLUORO-L-FUCOSE IN COMBINATION WITH A CHECKPOINT INHIBITOR

 #50 | 2018-09-06 ✅ Patent 10,669,348 granted on 2020-06-02
US20180251566A1
Chemistry; metallurgy

Antibody drug conjugates (ADC) that bind to 158P1D7 proteins

 #51 | 2018-06-21 ✅ Patent 10,912,842 granted on 2021-02-09
US20180169261A1
Human necessities

CD123 antibodies and conjugates thereof

 #52 | 2018-06-21 ✅ Patent 11,351,269 granted on 2022-06-07
US20180169257A1
Human necessities

Anti-NTB-A antibodies and related compositions and methods

 #53 | 2018-06-07 ✅ Patent 10,443,035 granted on 2019-10-15
US20180155677A1
Chemistry; metallurgy

Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation

 #54 | 2018-05-10 ✅ Patent 10,414,826 granted on 2019-09-17
US20180127512A1
Chemistry; metallurgy

Monomethylvaline compounds capable of conjugation to ligands

 #55 | 2018-04-05 ✅ Patent 10,722,592 granted on 2020-07-28
US20180092984A1
Human necessities

CD48 antibodies and conjugates thereof

 #56 | 2018-03-29
US20180085056A1
Human necessities

Sensory Apparatus for Detection of Peripheral Neuropathy

 #57 | 2018-02-01
US20180028681A1
Human necessities

COMBINATION THERAPY USING A CD19-ADC AND VINCRISTINE

 #58 | 2017-11-23 ✅ Patent 11,213,584 granted on 2022-01-04
US20170333556A1
Human necessities

Dosage and administration of non-fucosylated anti-CD40 antibodies

 #59 | 2017-11-09 ✅ Patent 10,435,468 granted on 2019-10-08
US20170320944A1
Chemistry; metallurgy

Anti-NTB-A antibodies and related compositions and methods

 #60 | 2017-10-19 ✅ Patent 10,329,352 granted on 2019-06-25
US20170298137A1
Chemistry; metallurgy

Pyrrolobenzodiazepines and targeted conjugates

 #61 | 2017-10-19
US20170298118A1
Chemistry; metallurgy

METHODS FOR SCREENING ANTIBODIES

 #62 | 2017-10-12 ✅ Patent 10,328,084 granted on 2019-06-25
US20170290924A1
Human necessities

Pyrrolobenzodiazepines and targeted conjugates

 #63 | 2017-10-05 ✅ Patent 10,098,963 granted on 2018-10-16
US20170281794A1
Human necessities

Weekly dosing regimens for anti-CD30 VC-PAB-MMAE antibody drug-conjugates

 #64 | 2017-08-31
US20170247412A1
Chemistry; metallurgy

TARGETED DELIVERY OF TERTIARY AMINE-CONTAINING DRUG SUBSTANCES

 #65 | 2017-08-17
US20170233484A1
Chemistry; metallurgy

BCMA ANTIBODIES AND USE OF SAME TO TREAT CANCER AND IMMUNOLOGICAL DISORDERS

 #66 | 2017-08-17 ✅ Patent 9,987,374 granted on 2018-06-05
US20170232112A1
Human necessities

Cyclodextrin and antibody-drug conjugate formulations

 #67 | 2017-08-03 ✅ Patent 10,933,112 granted on 2021-03-02
US20170216391A1
Human necessities

Hydrophilic antibody-drug conjugates

 #68 | 2017-07-20 ✅ Patent 10,787,514 granted on 2020-09-29
US20170204180A1
Chemistry; metallurgy

CD33 antibodies and use of same to treat cancer

 #69 | 2017-07-06
US20170189542A1
Human necessities

BETA-GLUCURONIDE-LINKER DRUG CONJUGATES

 #70 | 2017-07-06
US20170189540A9
Human necessities

BETA-GLUCURONIDE-LINKER DRUG CONJUGATES

 #71 | 2017-06-29
US20170182178A1
Human necessities

OPTIMAL DOSING OF A CD19-ANTIBODY DRUG CONJUGATE

 #72 | 2017-06-08 ✅ Patent 10,457,976 granted on 2019-10-29
US20170159099A1
Chemistry; metallurgy

Preparing antibodies from CHO cell cultures for conjugation

 #73 | 2017-05-18 ✅ Patent 11,202,827 granted on 2021-12-21
US20170137528A1
Chemistry; metallurgy

Dosage and administration of non-fucosylated anti-CD40 antibodies

 #74 | 2017-02-09 ✅ Patent 10,342,811 granted on 2019-07-09
US20170035790A1
Human necessities

Methods of inhibition of protein fucosylation in vivo using fucose analogs

 #75 | 2017-02-02
US20170028062A1
Human necessities

STABLE FORMULATIONS FOR ANTI-CD19 ANTIBODIES AND ANTIBODY-DRUG CONJUGATES

 #76 | 2017-01-26 ✅ Patent 9,701,752 granted on 2017-07-11
US20170022282A1
Chemistry; metallurgy

Humanized anti-CD70 binding agents and uses thereof

 #77 | 2016-12-22 ✅ Patent 9,926,376 granted on 2018-03-27
US20160369003A1
Chemistry; metallurgy

Antibody drug conjugates (ADC) that bind to 158P1D7 proteins

 #78 | 2016-12-22 ✅ Patent 10,407,505 granted on 2019-09-10
US20160367697A1
Human necessities

Variant target binding agents and uses thereof

 #79 | 2016-12-01 ✅ Patent 10,464,997 granted on 2019-11-05
US20160347824A1
Chemistry; metallurgy

Selective reduction of proteins

 #80 | 2016-10-27 ✅ Patent 11,103,593 granted on 2021-08-31
US20160310612A1
Human necessities

Pegylated drug-linkers for improved ligand-drug conjugate pharmacokinetics

 #81 | 2016-10-06 ✅ Patent 9,713,647 granted on 2017-07-25
US20160289239A1
Chemistry; metallurgy

Pyrrolobenzodiazepines and targeted conjugates

 #82 | 2016-10-06 ✅ Patent 9,707,301 granted on 2017-07-18
US20160287721A1
Human necessities

Pyrrolobenzodiazepines and targeted conjugates

 #83 | 2016-09-15 ✅ Patent 9,962,454 granted on 2018-05-08
US20160263243A1
Human necessities

Antibody drug conjugates (ADC) that bind to 191P4D12 proteins

 #84 | 2016-08-04 ✅ Patent 10,201,615 granted on 2019-02-12
US20160220693A1
Human necessities

Synergistic effects between auristatin-based antibody drug conjugates and inhibitors of the PI3K-AKT mTOR pathway

 #85 | 2016-07-07
US20160193359A1
Human necessities

NEW BINDER-DRUG CONJUGATES (ADCS) AND USE THEREOF

 #86 | 2016-06-30 ✅ Patent 9,783,608 granted on 2017-10-10
US20160185858A1
Chemistry; metallurgy

Humanized antibodies to LIV-1 and use of same to treat cancer

 #87 | 2016-05-12 ✅ Patent 9,713,648 granted on 2017-07-25
US20160129130A1
Human necessities

Weekly dosing regimens for anti-CD30 VC-PAB-MMAE antibody drug-conjugates

 #88 | 2016-05-12 ✅ Patent 9,592,240 granted on 2017-03-14
US20160129013A1
Human necessities

Targeted pyrrolobenzodiazapine conjugates

 #89 | 2016-02-18 ✅ Patent 9,610,361 granted on 2017-04-04
US20160045615A1
Human necessities

Cyclodextrin and antibody-drug conjugate formulations

 #90 | 2016-02-11 ✅ Patent 9,453,046 granted on 2016-09-27
US20160039870A1
Chemistry; metallurgy

Activated carbon filtration for purification of benzodiazepine ADCs

 #91 | 2016-01-14 ✅ Patent 9,493,566 granted on 2016-11-15
US20160009806A1
Chemistry; metallurgy

Antibodies to integrin AVB6 and use of same to treat cancer

 #92 | 2016-01-07
US20160003847A1
Physics

Detection and Treatment of Pancreatic, Ovarian and Other CD70 Positive Cancers

 #93 | 2015-12-31 ✅ Patent 9,708,404 granted on 2017-07-18
US20150376276A1
Chemistry; metallurgy

Anti-NTB-A antibodies and related compositions and methods

 #94 | 2015-11-26 ✅ Patent 9,816,069 granted on 2017-11-14
US20150337259A1
Chemistry; metallurgy

Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation

 #95 | 2015-10-29 ✅ Patent 9,314,538 granted on 2016-04-19
US20150306245A1
Human necessities

Nucleic acid molecules encoding antibody drug conjugates (ADC) that bind to 191P4D12 proteins

 #96 | 2015-10-08 ✅ Patent 9,919,061 granted on 2018-03-20
US20150283255A1
Human necessities

CD19 binding agents and uses thereof

 #97 | 2015-09-03
US20150246136A1
Human necessities

NOVEL BINDER-DRUG CONJUGATES (ADCs) AND USE OF SAME

 #98 | 2015-08-27 ✅ Patent 10,350,228 granted on 2019-07-16
US20150238509A1
Human necessities

Treatment of sickle cell disease and inflammatory conditions

 #99 | 2015-05-28
US20150148298A1
Chemistry; metallurgy

N-CARBOXYALKYL-AURISTATIN AND USE THEREOF

 #100 | 2015-05-28 ✅ Patent 9,587,019 granted on 2017-03-07
US20150147316A1
Chemistry; metallurgy

CD33 antibodies and use of same to treat cancer

Also check out SEATTLE GENETICS, INC.'s (Bothell, United States) applicant profile with 61 patent applications submitted.

AssigneeID:

5872 ⎘